Skip to main content
Article thumbnail
Location of Repository

The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism

By K.W. Muir
Publisher: American Heart Association
Year: 2008
OAI identifier: oai:eprints.gla.ac.uk:17885
Provided by: Enlighten

Suggested articles

Citations

  1. (2002). Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev. doi
  2. (1987). Autopsy-verified causes of death after stroke. Acta Med Scand. doi
  3. (1991). Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis. Am J Phys Med Rehabil. doi
  4. Deep venous thrombosis of the legs after strokes: part 2—natural history. doi
  5. Deep venous thrombosis of the legs after strokes. Part I—incidence and predisposing factors. doi
  6. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. doi
  7. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. doi
  8. (2005). Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev. doi
  9. Natural history of venous thromboembolism. doi
  10. (1998). Pneumatic sequential compression reduces the risk of deep vein thrombosis in stroke patients. doi
  11. (1997). Pulmonary embolism associated with acute stroke. Mayo Clin
  12. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL study): an open-label randomised comparison. doi
  13. Tinzaparin in Acute Ischaemic Stroke (TAIST): a randomised aspirin-controlled trial. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.